While inhibition of NF-κB can kill DLBCL cells, the ubiquitous role of NF-κB creates severe on-target toxicities, which precludes the clinical use of broad NF-κB inhibitors (38, 39). The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.